Trachoma is a neglected tropical disease caused by conjunctival infection with Chlamydia trachomatis, leading to chronic conjunctival inflammation, scarring, trichiasis, and blindness.
Ask a research question about Trachoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Trachoma
creation_date: '2026-01-26T15:56:41Z'
updated_date: '2026-04-11T01:06:52Z'
category: Infectious Disease
description: >-
Trachoma is a neglected tropical disease caused by conjunctival infection with
Chlamydia trachomatis, leading to chronic conjunctival inflammation, scarring,
trichiasis, and blindness.
disease_term:
term:
id: MONDO:0001249
label: trachoma
preferred_term: Trachoma
parents:
- Bacterial Infection
- Neglected tropical disease
infectious_agent:
- name: Chlamydia trachomatis
infectious_agent_term:
preferred_term: Chlamydia trachomatis
term:
id: NCBITaxon:813
label: Chlamydia trachomatis
description: Conjunctival strains of C. trachomatis cause trachoma.
evidence:
- reference: PMID:35618795
reference_title: "Trachoma."
supports: SUPPORT
snippet: "Trachoma is a neglected tropical disease caused by infection with conjunctival strains of Chlamydia trachomatis."
explanation: The abstract identifies conjunctival C. trachomatis as the cause of trachoma.
pathophysiology:
- name: Chronic conjunctival infection with scarring
description: Recurrent infection drives chronic inflammation and scarring leading to trichiasis.
evidence:
- reference: PMID:35618795
reference_title: "Trachoma."
supports: SUPPORT
snippet: "Trachoma is a disease complex composed of two linked chronic processes: a recurrent, generally subclinical infectious-inflammatory disease that mostly affects children, and a non-communicable, cicatricial and, owing to trichiasis, eventually blinding disease"
explanation: The abstract describes chronic infection progressing to cicatricial disease with trichiasis.
phenotypes:
- name: Blindness
category: Ophthalmologic
frequency: OCCASIONAL
phenotype_term:
preferred_term: Blindness
term:
id: HP:0000618
label: Blindness
evidence:
- reference: PMID:35618795
reference_title: "Trachoma."
supports: SUPPORT
snippet: "Trachoma is a neglected tropical disease caused by infection with conjunctival strains of Chlamydia trachomatis. It can result in blindness."
explanation: The abstract notes that trachoma can result in blindness.
treatments:
- name: Antibiotic mass drug administration (SAFE strategy)
description: Antibiotic mass drug administration reduces infection prevalence and transmission.
treatment_term:
preferred_term: antibiotic therapy
term:
id: NCIT:C15620
label: Antibiotic Therapy
evidence:
- reference: PMID:35618795
reference_title: "Trachoma."
supports: SUPPORT
snippet: "Surgery is offered to individuals with trichiasis and antibiotic mass drug administration and interventions to stimulate facial cleanliness and environmental improvement are designed to reduce infection prevalence and transmission."
explanation: The abstract describes antibiotic mass drug administration as part of SAFE.
references:
- reference: DOI:10.1038/s41598-024-71201-z
title: 'Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022'
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: 'Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022'
supporting_text: Mozambique is making progress towards elimination of trachoma as a public health problem, but in some districts trachomatous inflammation—follicular (TF) prevalence remains above the 5% elimination threshold despite years of various interventions, including antibiotic mass drug administration.
evidence:
- reference: DOI:10.1038/s41598-024-71201-z
reference_title: 'Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Mozambique is making progress towards elimination of trachoma as a public health problem, but in some districts trachomatous inflammation—follicular (TF) prevalence remains above the 5% elimination threshold despite years of various interventions, including antibiotic mass drug administration.
explanation: Deep research cited this publication as relevant literature for Trachoma.
- reference: DOI:10.1038/sj.gene.6364384
title: Genetic variation at the TNF locus and the risk of severe sequelae of ocular Chlamydia trachomatis infection in Gambians
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: Genetic variation at the TNF locus and the risk of severe sequelae of ocular Chlamydia trachomatis infection in Gambians
supporting_text: Genetic variation at the TNF locus and the risk of severe sequelae of ocular Chlamydia trachomatis infection in Gambians
- reference: DOI:10.1080/09286586.2023.2249546
title: 'Tropical Data: Approach and Methodology as Applied to Trachoma Prevalence Surveys'
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: 'Tropical Data: Approach and Methodology as Applied to Trachoma Prevalence Surveys'
supporting_text: 'Tropical Data: Approach and Methodology as Applied to Trachoma Prevalence Surveys'
- reference: DOI:10.1155/2015/791847
title: Trachoma and Ocular Chlamydial Infection in the Era of Genomics
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: Trachoma is a blinding disease usually caused by infection with Chlamydia trachomatis (Ct) serovars A, B, and C in the upper tarsal conjunctiva.
supporting_text: Trachoma is a blinding disease usually caused by infection with Chlamydia trachomatis (Ct) serovars A, B, and C in the upper tarsal conjunctiva.
evidence:
- reference: DOI:10.1155/2015/791847
reference_title: Trachoma and Ocular Chlamydial Infection in the Era of Genomics
supports: SUPPORT
evidence_source: OTHER
snippet: Trachoma is a blinding disease usually caused by infection with Chlamydia trachomatis (Ct) serovars A, B, and C in the upper tarsal conjunctiva.
explanation: Deep research cited this publication as relevant literature for Trachoma.
- reference: DOI:10.1371/journal.pntd.0012388
title: Multimodal mucosal and systemic immune characterization of a non-human primate trachoma model highlights the critical role of local immunity during acute phase disease
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: Trachoma is a leading cause of infection-related blindness worldwide.
supporting_text: Trachoma is a leading cause of infection-related blindness worldwide.
evidence:
- reference: DOI:10.1371/journal.pntd.0012388
reference_title: Multimodal mucosal and systemic immune characterization of a non-human primate trachoma model highlights the critical role of local immunity during acute phase disease
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Trachoma is a leading cause of infection-related blindness worldwide.
explanation: Deep research cited this publication as relevant literature for Trachoma.
- reference: DOI:10.1371/journal.pone.0003600
title: Identification of Novel Single Nucleotide Polymorphisms in Inflammatory Genes as Risk Factors Associated with Trachomatous Trichiasis
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: Identification of Novel Single Nucleotide Polymorphisms in Inflammatory Genes as Risk Factors Associated with Trachomatous Trichiasis
supporting_text: Identification of Novel Single Nucleotide Polymorphisms in Inflammatory Genes as Risk Factors Associated with Trachomatous Trichiasis
- reference: DOI:10.1590/0037-8682-0158-2024
title: 'Trachoma-associated morbidity and mortality in Brazil: an ecological study focusing on hospitalization and mortality data, 2000−2022'
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: 'Trachoma-associated morbidity and mortality in Brazil: an ecological study focusing on hospitalization and mortality data, 2000−2022'
supporting_text: 'Trachoma-associated morbidity and mortality in Brazil: an ecological study focusing on hospitalization and mortality data, 2000−2022'
- reference: DOI:10.3390/microorganisms12081544
title: Insights into Pathogenesis of Trachoma
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: Trachoma is the most common infectious cause of blindness worldwide.
supporting_text: Trachoma is the most common infectious cause of blindness worldwide.
evidence:
- reference: DOI:10.3390/microorganisms12081544
reference_title: Insights into Pathogenesis of Trachoma
supports: SUPPORT
evidence_source: OTHER
snippet: Trachoma is the most common infectious cause of blindness worldwide.
explanation: Deep research cited this publication as relevant literature for Trachoma.
- reference: DOI:10.5772/intechopen.111372
title: Chlamydial Eye Infections
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: Chlamydiae are obligate intracellular bacteria causing mucosal infections.
supporting_text: Chlamydiae are obligate intracellular bacteria causing mucosal infections.
evidence:
- reference: DOI:10.5772/intechopen.111372
reference_title: Chlamydial Eye Infections
supports: SUPPORT
evidence_source: OTHER
snippet: Chlamydiae are obligate intracellular bacteria causing mucosal infections.
explanation: Deep research cited this publication as relevant literature for Trachoma.
- reference: DOI:10.7759/cureus.52358
title: 'Eliminating Trachoma in Africa: The Importance of Environmental Interventions'
found_in:
- Trachoma-deep-research-falcon.md
findings:
- statement: 'Eliminating Trachoma in Africa: The Importance of Environmental Interventions'
supporting_text: 'Eliminating Trachoma in Africa: The Importance of Environmental Interventions'
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Trachoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Trachoma is a neglected tropical eye disease caused by conjunctival strains/serovars A–C of Chlamydia trachomatis and is the leading infectious cause of blindness globally. Repeated ocular infections in childhood drive chronic conjunctival inflammation that can progress to conjunctival scarring, trichiasis, corneal opacity, and irreversible visual impairment or blindness. Control and elimination efforts are organized around WHO’s SAFE strategy (Surgery, Antibiotics, Facial cleanliness, Environmental improvement) and population-based prevalence surveys graded with the WHO simplified system. Recent work (2023–2024) emphasizes improved surveillance in low-prevalence/post-MDA settings using nucleic acid amplification tests (NAATs) and serology (e.g., Pgp3 antibodies) because clinical TF correlates imperfectly with ocular infection after MDA. (sitoe2024ongoingtransmissionof pages 1-2, ageed2024eliminatingtrachomain pages 2-3)
Trachoma is an infectious conjunctivitis/keratoconjunctivitis caused by ocular strains of Chlamydia trachomatis; repeated infection episodes lead to chronic inflammation and a cicatricial disease that may culminate in trichiasis and corneal opacity/blindness. (sahin2023chlamydialeyeinfections pages 1-4, sitoe2024ongoingtransmissionof pages 1-2)
Because these identifiers are typically available from controlled vocabularies (e.g., MeSH, ICD, MONDO) rather than primary papers, and were not present in the retrieved texts, this report cannot provide verified codes without additional ontology/database retrieval.
The information summarized here is predominantly from aggregated disease-level resources and population-based survey literature (WHO-aligned grading and elimination criteria; country surveys; systematic reviews) rather than from EHR-derived patient-level datasets. (hardingesch2023tropicaldataapproach pages 1-2, antwiadjei2017relationshipbetweenthe pages 29-35)
Transmission routes: Direct or indirect transfer of ocular/nasal secretions (including fomites) and mechanical transmission via flies are emphasized in recent reviews and programmatic literature. (sahin2023chlamydialeyeinfections pages 1-4, toumasis2024insightsintopathogenesis pages 10-12, ageed2024eliminatingtrachomain pages 2-3)
Environmental and social risk factors: Overcrowding and poor hygiene/sanitation are consistently linked to higher transmission intensity; recent syntheses stress WASH and fly control as key determinants of sustained transmission. (toumasis2024insightsintopathogenesis pages 10-12, ageed2024eliminatingtrachomain pages 2-3)
Protective factors supported in the retrieved evidence are primarily environmental/behavioral: improved access to water for hygiene, sanitation (latrine access/use), facial cleanliness, and reductions in fly–eye contact are repeatedly cited as associated with lower risk/prevalence. (ageed2024eliminatingtrachomain pages 2-3)
While trachoma is not a monogenic disorder, multiple studies support the concept that host immune-genetic variation modifies risk of severe sequelae (scarring, trichiasis) given similar exposure, implying gene–environment interaction (host variants shaping inflammatory/fibrotic response in settings with repeated infection). (derrick2015trachomaandocular pages 5-6, atik2008identificationofnovel pages 2-3)
WHO’s simplified clinical grading system defines five key signs (TF, TI, TS, TT, CO), used in field surveys and elimination decision-making. Exact definitions from a WHO-aligned grading summary are provided in the artifact table. (antwiadjei2017relationshipbetweenthe pages 29-35)
HPO term suggestions (non-exhaustive): * Follicular conjunctivitis (TF): HP:0000509 (Conjunctivitis) + HP:0030057 (Follicular conjunctivitis; if not available, use conjunctivitis with qualifier) * Conjunctival scarring (TS): HP:0031095 (Conjunctival scarring; if unavailable, map to conjunctival fibrosis) * Trichiasis (TT): HP:0009796 (Trichiasis) * Entropion (often accompanying TT): HP:0000656 (Entropion) * Corneal opacity (CO): HP:0007957 (Corneal opacity) * Visual impairment/blindness (advanced): HP:0000505 (Visual impairment), HP:0000618 (Blindness)
Trachoma commonly begins in childhood as “active” disease (TF/TI), and later in life a subset develop progressive scarring and trichiasis, which can continue even when ocular infection is no longer detectable—emphasizing a chronic, scarring phenotype with long latency. (toumasis2024insightsintopathogenesis pages 9-10, sitoe2024ongoingtransmissionof pages 1-2)
Advanced disease (TT/CO) causes pain (from lashes rubbing cornea), ocular surface damage, and progressive visual impairment/blindness, with major functional and socioeconomic consequences in endemic, low-resource communities. (ageed2024eliminatingtrachomain pages 2-3)
Trachoma is not caused by pathogenic germline variants in a single gene; instead, genetic evidence supports susceptibility modifiers affecting inflammatory and fibrotic responses.
Evidence includes HLA/KIR, cytokine/TNF-region, and other inflammatory pathway variants associated with scarring and/or trichiasis in population studies: * HLA-C2 dose effect with scarring risk in Gambians; risk further increased by KIR2DL2/KIR2DL3 heterozygosity (reviewed with reported ORs up to ~5.95 in HLA-C2 homozygotes with both KIR2DL2 and KIR2DL3). (derrick2015trachomaandocular pages 5-6) * TNF-locus region variants associated with severe sequelae in Gambians, including TNF promoter and linked-region SNPs; e.g., TNF-308A (dominant) associated with increased trichiasis risk (OR 1.52, 95% CI 1.07–2.15) and TNF-238 associated with scarring in one analysis (OR 1.46, 95% CI 1.06–2.01). (natividad2007geneticvariationat pages 2-3) * Nepal (Tharu ethnicity) TT risk/protection combinations across inflammatory genes (logic regression). A protective multilocus combination was associated with ~5-fold lower TT risk (OR 0.2, 95% CI 0.11–0.33), while a risk combination was associated with substantially higher TT risk (OR 13.5, 95% CI 3.3–22). (atik2008identificationofnovel pages 1-2)
A genomics-focused synthesis emphasizes that many reported associations have modest sample sizes, multiple-testing/epistasis concerns, and heterogeneous phenotyping across settings; overall, the weight of evidence supports polygenic, context-dependent susceptibility rather than deterministic variants. (derrick2015trachomaandocular pages 5-6)
Key environmental drivers in endemic settings include limited WASH infrastructure and fly breeding conditions (e.g., sanitation and exposed feces), which influence exposure intensity and reinfection rates. Environmental improvement (latrines/sanitation, water access for hygiene, fly control) is repeatedly described as central to sustained transmission reduction beyond the transient impact of antibiotic campaigns. (toumasis2024insightsintopathogenesis pages 10-12, ageed2024eliminatingtrachomain pages 2-3)
Suggested GO Biological Process terms (examples): * GO:0006954 inflammatory response * GO:0006955 immune response * GO:0007165 signal transduction (innate immune receptor pathways) * GO:0030198 extracellular matrix organization * GO:0043062 extracellular structure organization * GO:0001525 angiogenesis (pannus/vascularization in chronic disease; referenced in clinical descriptions) (sahin2023chlamydialeyeinfections pages 1-4)
Suggested CL cell types (examples): * CL:0000066 epithelial cell (conjunctival epithelial) * CL:0000451 dendritic cell (antigen presentation) * CL:0000542 lymphocyte (T cell subsets) * CL:0000236 B cell * CL:0000623 natural killer cell (noted in genetic models involving KIR/HLA and conjunctival infiltrates in scarring disease) (derrick2015trachomaandocular pages 5-6)
UBERON term suggestions: * Conjunctiva: UBERON:0000970 * Eyelid: UBERON:0001711 * Cornea: UBERON:0000964
Typically begins in childhood as active disease (TF/TI), with chronic consequences manifesting later after cumulative infections. (sitoe2024ongoingtransmissionof pages 1-2, antwiadjei2017relationshipbetweenthe pages 29-35)
Progression is generally chronic and cumulative; repeated reinfection/inflammation increases scarring risk, and established scarring can continue to progress over years, necessitating long-term services for TT even after infection prevalence decreases. (toumasis2024insightsintopathogenesis pages 9-10, sitoe2024ongoingtransmissionof pages 1-2)
Global endemicity and burden: * A Brazil-focused 2024 ecological study cites that in 2023, 115.7 million people lived in trachoma-endemic regions, with 1.5 million experiencing sequelae, across 40 countries. (maciel2024trachomaassociatedmorbidityand pages 1-2) * In program operations literature (Tropical Data), trachoma surveys have been scaled: between 29 Feb 2016 and 24 Apr 2023, 3,373 surveys across 50 countries examined 10,818,502 people. (hardingesch2023tropicaldataapproach pages 1-2)
Country/program example (Mozambique): * Baseline mapping (2011–2015) and SAFE led to large-scale reductions; by 2022, 54 of 66 endemic districts in Mozambique had stopped MDA after reaching TF <5%, but persistent/recrudescent TF remained in a subset. (sitoe2024ongoingtransmissionof pages 2-3)
Active trachoma is concentrated in children (1–9 years used for TF-based decision thresholds), while TT is measured in adults (≥15 years) and reflects cumulative exposure and scarring. (sitoe2024ongoingtransmissionof pages 1-2, hardingesch2023tropicaldataapproach pages 1-2)
Genetic susceptibility is multifactorial; associations include HLA/KIR and cytokine-region variants across African and Asian populations, but these do not imply Mendelian inheritance patterns for the disease. (derrick2015trachomaandocular pages 5-6, atik2008identificationofnovel pages 1-2)
Clinical diagnosis and population monitoring rely on the WHO simplified grading system (TF/TI/TS/TT/CO). (antwiadjei2017relationshipbetweenthe pages 29-35)
A key 2024 Mozambique analysis argues that in low-prevalence/post-MDA settings, TF does not consistently correlate with ocular infection, motivating adjunct testing: * NAAT/PCR from conjunctival swabs for ocular C. trachomatis nucleic acid. (sitoe2024ongoingtransmissionof pages 1-2) * Serology from dried blood spots, particularly anti-Pgp3 antibodies; Mozambique field surveys implemented multiplex bead assays and modeled seroconversion rates as an indicator of transmission intensity. (sitoe2024ongoingtransmissionof pages 1-2, sitoe2024ongoingtransmissionof pages 3-4)
Concrete 2022 Mozambique enhanced survey data (children 1–9 years): * TF: 1.1–6.0% * PCR infection: 1.1–4.8% * Pgp3 seroprevalence: 8.8–24.3% * Pgp3 seroconversion rate: 1.9–6.0 per 100 children-year These discordances illustrate how TF, PCR infection, and serology can diverge and why multi-indicator surveillance is being operationalized. (sitoe2024ongoingtransmissionof pages 1-2, sitoe2024ongoingtransmissionof pages 4-6)
Not comprehensively extractable from the retrieved evidence in this run; clinically, other causes of chronic/follicular conjunctivitis (viral, allergic, other bacterial) are typical differentials, but specific evidence-backed differentials were not captured in the cited texts.
The major morbidity is vision loss due to corneal opacity following trichiasis-related corneal damage. Trachoma is a long-latency disease; even after transmission wanes, TT services may be needed for years because scarring disease can persist/progress. (sitoe2024ongoingtransmissionof pages 1-2, antwiadjei2017relationshipbetweenthe pages 29-35)
SAFE remains the backbone of trachoma management and elimination: * Surgery: for TT; one described approach is bilamellar tarsal rotation procedure (BTRP). (ageed2024eliminatingtrachomain pages 2-3) * Antibiotics: typically azithromycin mass drug administration (MDA) as the population-level antibiotic arm. (sitoe2024ongoingtransmissionof pages 1-2) * Facial cleanliness and Environmental improvement: to reduce reinfection/transmission and sustain gains. (sitoe2024ongoingtransmissionof pages 1-2, ageed2024eliminatingtrachomain pages 2-3)
MAXO term suggestions: * Antibiotic therapy: MAXO:0000058 (if using a general antibiotic therapy term) * Mass drug administration: MAXO term not confirmed in retrieved evidence; would be mapped under population-level preventive treatment. * Trichiasis surgery / eyelid surgery: MAXO:0001070 (surgical procedure; specify eyelid correction if available)
WHO-aligned operational thresholds for district-level decisions based on TF in children 1–9 years include: * TF ≥30% → ≥5 years A/F/E * TF 10–29.9% → 3 years A/F/E * TF 5–9.9% → 1 year A/F/E * TF <5% → transition away from district-wide A/F/E toward surveillance (hardingesch2023tropicaldataapproach pages 1-2)
Recent program evaluations emphasize that in post-MDA settings, clinical signs may not track infection; therefore NAAT/PCR and serology are being incorporated into surveillance to inform decisions and monitor potential ongoing transmission. (sitoe2024ongoingtransmissionof pages 1-2)
Primary prevention is dominated by SAFE’s F and E components (facial cleanliness, sanitation, water access, fly control) and broader socioeconomic improvements. (toumasis2024insightsintopathogenesis pages 10-12, ageed2024eliminatingtrachomain pages 2-3)
Population-based prevalence surveys (TIS/TSS) using WHO simplified grading are central; Tropical Data provides standardized methodologies and electronic data capture to support ministries of health in survey-based decision making. (hardingesch2023tropicaldataapproach pages 1-2)
Timely surgery for TT prevents continued corneal abrasion and reduces progression to corneal opacity and blindness. (ageed2024eliminatingtrachomain pages 2-3, antwiadjei2017relationshipbetweenthe pages 29-35)
This run retrieved an NHP experimental infection model used to study acute trachoma-like disease and local immune responses, supporting comparative pathology and vaccine research. (paulet2024multimodalmucosaland pages 21-22)
A 2024 PLOS NTD study reports an NHP conjunctival C. trachomatis infection model with clinical findings similar to acute human trachoma and a staged conjunctival immune response, positioning this model for preclinical evaluation of vaccines/therapeutics. (paulet2024multimodalmucosaland pages 21-22)
The retrieved evidence in this run included review-level discussion of immune pathways and tissue remodeling; detailed single-cell/spatial multi-omics for trachoma specifically was not captured in the cited evidence.
| Category | Item | Exact definition / key finding | Year / threshold | Evidence |
|---|---|---|---|---|
| Definition / agent | Trachoma | Neglected tropical eye disease caused by conjunctival strains/serovars A-C of Chlamydia trachomatis; repeated childhood ocular infection leads to conjunctival scarring, trichiasis, corneal opacity, and blindness | Current understanding | (sahin2023chlamydialeyeinfections pages 1-4, sitoe2024ongoingtransmissionof pages 1-2, hardingesch2023tropicaldataapproach pages 1-2) |
| WHO simplified grading | TF | Trachomatous inflammation-follicular: presence of 5 or more follicles, each at least 0.5 mm diameter, in the central part of the upper tarsal conjunctiva | WHO field grade | (antwiadjei2017relationshipbetweenthe pages 29-35) |
| WHO simplified grading | TI | Trachomatous inflammation-intense: pronounced inflammatory thickening of the upper tarsal conjunctiva obscuring more than half of the normal deep tarsal vessels | WHO field grade | (antwiadjei2017relationshipbetweenthe pages 29-35) |
| WHO simplified grading | TS | Trachomatous scarring: easily visible scars in the tarsal conjunctiva | WHO field grade | (antwiadjei2017relationshipbetweenthe pages 29-35) |
| WHO simplified grading | TT | Trachomatous trichiasis: at least one eyelash rubbing on the eyeball, or evidence of recent removal of in-turned eyelashes | WHO field grade | (antwiadjei2017relationshipbetweenthe pages 29-35) |
| WHO simplified grading | CO | Corneal opacity: easily visible corneal opacity over the pupil, dense enough that at least part of the pupil margin is blurred | WHO field grade | (antwiadjei2017relationshipbetweenthe pages 29-35) |
| Elimination criteria | TT criterion | TT unknown to the health system in adults aged ≥15 years must be <0.2% in each formerly endemic district | WHO elimination as a public health problem | (sitoe2024ongoingtransmissionof pages 1-2, hardingesch2023tropicaldataapproach pages 1-2) |
| Elimination criteria | TF criterion | TF in children aged 1-9 years must be <5% in each formerly endemic district | WHO elimination as a public health problem | (sitoe2024ongoingtransmissionof pages 1-2, hardingesch2023tropicaldataapproach pages 1-2) |
| Elimination criteria | Service criterion | Evidence that the health system can identify and manage incident TT cases | WHO elimination as a public health problem | (sitoe2024ongoingtransmissionof pages 1-2) |
| Programmatic TF thresholds | TF ≥30% | At least 5 years of A/F/E interventions (antibiotics, facial cleanliness, environmental improvement) | WHO programmatic threshold | (hardingesch2023tropicaldataapproach pages 1-2) |
| Programmatic TF thresholds | TF 10-29.9% | 3 years of A/F/E interventions | WHO programmatic threshold | (hardingesch2023tropicaldataapproach pages 1-2) |
| Programmatic TF thresholds | TF 5-9.9% | 1 year of A/F/E interventions | WHO programmatic threshold | (hardingesch2023tropicaldataapproach pages 1-2) |
| Programmatic TF thresholds | TF <5% | No further district-wide A/F/E intervention indicated; transition to surveillance/program review | WHO programmatic threshold | (antwiadjei2017relationshipbetweenthe pages 51-56, hardingesch2023tropicaldataapproach pages 1-2) |
| Control strategy | SAFE | Surgery for trichiasis; Antibiotics (usually azithromycin MDA); Facial cleanliness; Environmental improvement (water, sanitation, fly control) | Current WHO strategy | (sitoe2024ongoingtransmissionof pages 1-2, hardingesch2023tropicaldataapproach pages 1-2) |
| Epidemiology | Population in endemic regions | Estimated 115.7 million people resided in trachoma-endemic regions globally | 2023 | (maciel2024trachomaassociatedmorbidityand pages 1-2) |
| Epidemiology | People going blind | 1.8 million people worldwide were going blind from trachoma | June 2021 | (hardingesch2023tropicaldataapproach pages 1-2) |
| Epidemiology | Countries achieving elimination | 18 countries had achieved elimination as a public health problem | As of July 2023 | (sitoe2024ongoingtransmissionof pages 1-2) |
| Epidemiology | Endemic countries | Trachoma remained endemic in 40 countries | 2023 | (maciel2024trachomaassociatedmorbidityand pages 1-2) |
| Epidemiology / Mozambique | TF prevalence range | In four enhanced impact survey districts, TF prevalence in children 1-9 years ranged 1.1%-6.0% | Mozambique 2022 | (sitoe2024ongoingtransmissionof pages 1-2) |
| Epidemiology / Mozambique | PCR-confirmed ocular infection range | Ocular C. trachomatis nucleic acid prevalence ranged 1.1%-4.8% | Mozambique 2022 | (sitoe2024ongoingtransmissionof pages 1-2) |
| Epidemiology / Mozambique | Pgp3 seroprevalence range | Anti-Pgp3 seroprevalence ranged 8.8%-24.3% in children 1-9 years | Mozambique 2022 | (sitoe2024ongoingtransmissionof pages 1-2) |
| Epidemiology / Mozambique | Seroconversion rate range | Pgp3 seroconversion rates ranged 1.9-6.0 per 100 children per year | Mozambique 2022 | (sitoe2024ongoingtransmissionof pages 1-2) |
| Diagnostics | Clinical grading | Population-based surveys and bedside diagnosis primarily use the WHO simplified grading system | Standard programmatic method | (sitoe2024ongoingtransmissionof pages 1-2, hardingesch2023tropicaldataapproach pages 1-2, antwiadjei2017relationshipbetweenthe pages 29-35) |
| Diagnostics | NAAT / PCR | Conjunctival swab nucleic acid amplification testing detects ocular C. trachomatis infection and is useful where TF correlates poorly with infection after MDA | Current adjunct / research-programmatic use | (sahin2023chlamydialeyeinfections pages 1-4, sitoe2024ongoingtransmissionof pages 1-2) |
| Diagnostics | Pgp3 serology | Dried blood spot serology for anti-Pgp3 antibodies is a promising population-level indicator of transmission intensity and post-MDA surveillance | Current adjunct / research-programmatic use | (sitoe2024ongoingtransmissionof pages 1-2) |
Table: This table condenses core disease definitions, WHO grading and elimination thresholds, recent epidemiology, and practical diagnostics for trachoma. It is useful as a quick-reference artifact for a disease knowledge base entry with directly cited evidence.
URLs and dates are embedded in the cited sources’ metadata within this report; primary examples include: Scientific Reports (Oct 2024) Mozambique enhanced impact surveys (https://doi.org/10.1038/s41598-024-71201-z) (sitoe2024ongoingtransmissionof pages 1-2); Cureus (Jan 2024) environmental interventions review (https://doi.org/10.7759/cureus.52358) (ageed2024eliminatingtrachomain pages 2-3); Ophthalmic Epidemiology (Nov 2023) Tropical Data methods (https://doi.org/10.1080/09286586.2023.2249546) (hardingesch2023tropicaldataapproach pages 1-2).
References
(sitoe2024ongoingtransmissionof pages 1-2): Henis Sitoe, William Edward Oswald, Felizmina Zita, Mawo Fall, Tamimo Momade, Molly W Adams, Rebecca M Flueckiger, Scott McPherson, Sabrina Eyob, Thuy Doan, Thomas M Lietman, Benjamin F Arnold, Karana Wickens, Sarah Gwyn, Diana L Martin, Mabula Kasubi, Sarah Boyd, Ana Bakhtiari, Cristina Jimenez, Anthony W Solomon, Emma M Harding-Esch, and Jeremiah M Ngondi. Ongoing transmission of trachoma in low prevalence districts in mozambique: results from four cross-sectional enhanced impact surveys, 2022. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-71201-z, doi:10.1038/s41598-024-71201-z. This article has 3 citations and is from a peer-reviewed journal.
(ageed2024eliminatingtrachomain pages 2-3): Ahmed Ageed and Maaz Khan. Eliminating trachoma in africa: the importance of environmental interventions. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52358, doi:10.7759/cureus.52358. This article has 10 citations.
(sahin2023chlamydialeyeinfections pages 1-4): Seçil Özdemir Şahin. Chlamydial eye infections. Infectious Diseases, Jul 2023. URL: https://doi.org/10.5772/intechopen.111372, doi:10.5772/intechopen.111372. This article has 1 citations and is from a peer-reviewed journal.
(antwiadjei2017relationshipbetweenthe pages 29-35): EK Antwi-Adjei. Relationship between the prevalence of trachomatous inflammation in children (age 1-9years) and the prevalence of trichiasis in adults (age 15years and above) at a …. Unknown journal, 2017.
(hardingesch2023tropicaldataapproach pages 1-2): Emma M Harding-Esch, Clara R Burgert-Brucker, Cristina Jimenez, Ana Bakhtiari, Rebecca Willis, Michael Dejene Bejiga, Caleb Mpyet, Jeremiah Ngondi, Sarah Boyd, Mariamo Abdala, Amza Abdou, Yilikal Adamu, Addisu Alemayehu, Wondu Alemayehu, Tawfik Al-Khatib, Sue-Chen Apadinuwe, Naomie Awaca, Marcel S Awoussi, Gilbert Baayendag, Mouctar Dieng Badiane, Robin L Bailey, Wilfrid Batcho, Zulficar Bay, Assumpta Bella, Nassirou Beido, Yak Yak Bol, Clarisse Bougouma, Christopher J Brady, Victor Bucumi, Robert Butcher, Risiate Cakacaka, Anaseini Cama, Mamoudou Camara, Eunice Cassama, Shorai Grace Chaora, Amel Chenaoui Chebbi, Alvin Blessings Chisambi, Brian Chu, Abdulai Conteh, Sidi Mohamed Coulibaly, Paul Courtright, Abdi Dalmar, Tran Minh Dat, Thully Davids, Mohamed El Amine Djaker, Maria de Fátima Costa Lopes, Djore Dézoumbé, Sarity Dodson, Philip Downs, Stephanie Eckman, Bilghis Elkhair Elshafie, Mourad Elmezoghi, Ange Aba Elvis, Paul Emerson, Emilienne EE Epée, Daniel Faktaufon, Mawo Fall, Aréty Fassinou, Fiona Fleming, Rebecca Flueckiger, Koizan Kadjo Gamael, Mackline Garae, Jambi Garap, Katie Gass, Genet Gebru, Michael M Gichangi, Emanuele Giorgi, André Goépogui, Daniela Vaz Ferreira Gómez, Diana Paola Gómez Forero, Emily W Gower, Anna Harte, Rob Henry, Harvy Alberto Honorio-Morales, Dunera R Ilako, Amadou Alfa Bio Issifou, Ellen Jones, George Kabona, Martin Kabore, Boubacar Kadri, Khumbo Kalua, Sarjo Kebba Kanyi, Shambel Kebede, Fikreab Kebede, Jeremy D Keenan, Amir B Kello, Asad Aslam Khan, Houria Khelifi, Janvier Kilangalanga, Sung Hye Kim, Robert Ko, Susan Lewallen, Thomas Lietman, Makoy Samuel Yibi Logora, Yuri A Lopez, Chad MacArthur, Colin Macleod, Felix Makangila, Brehima Mariko, Diana L Martin, Michael Masika, Patrick Massae, Marilia Massangaie, Hadley S Matendechero, Tsedeke Mathewos, Siobhain McCullagh, Aboulaye Meite, Elsa Palma Mendes, Hirpa M Abdi, Hollman Miller, Abdellahi Minnih, Sailesh Kumar Mishra, Tuduetso Molefi, Aryc Mosher, Nerkoua M’Po, Francis Mugume, Robson Mukwiza, Consity Mwale, Stephen Mwatha, Upendo Mwingira, Scott D Nash, Christophe Nassa, Nebiyu Negussu, Cece Nieba, Jean Claude Noah Noah, Christian O Nwosu, Nicholas Olobio, Rapheal Opon, Alexandre Pavluck, Isaac Phiri, Merelesita Rainima-Qaniuci, Kristen K Renneker, Martha Idalí Saboyá-Díaz, Fatoumata Sakho, Salimato Sanha, Virginia Sarah, Boubacar Sarr, Celia L Szwarcwald, Ahmad Shah Salam, Shekhar Sharma, Fikre Seife, Gloria Marina Serrano Chavez, Mactar Sissoko, Henis Mior Sitoe, Oliver Sokana, Fentahun Tadesse, Fasiah Taleo, Sandra Liliana Talero, Youcef Tarfani, Amsayaw Tefera, Rabebe Tekeraoi, Andeberhan Tesfazion, Abubaker Traina, Lamine Traoré, Julián Trujillo-Trujillo, Edridah M Tukahebwa, Praveen Vashist, Ernest B Wanyama, Supriya D.P. Warusavithana, Titus K Watitu, Sheila West, Ye Win, Geordie Woods, Aya Yajima, Georges Yaya, Alem Zecarias, Solomon Zewengiel, Akoi Zoumanigui, Pamela J Hooper, Tom Millar, Lisa Rotondo, and Anthony W Solomon. Tropical data: approach and methodology as applied to trachoma prevalence surveys. Ophthalmic Epidemiology, 30:544-560, Nov 2023. URL: https://doi.org/10.1080/09286586.2023.2249546, doi:10.1080/09286586.2023.2249546. This article has 40 citations and is from a peer-reviewed journal.
(toumasis2024insightsintopathogenesis pages 9-10): Panagiotis Toumasis, Georgia Vrioni, Ioannis T. Tsinopoulos, Maria Exindari, and George Samonis. Insights into pathogenesis of trachoma. Microorganisms, 12:1544, Jul 2024. URL: https://doi.org/10.3390/microorganisms12081544, doi:10.3390/microorganisms12081544. This article has 5 citations.
(toumasis2024insightsintopathogenesis pages 10-12): Panagiotis Toumasis, Georgia Vrioni, Ioannis T. Tsinopoulos, Maria Exindari, and George Samonis. Insights into pathogenesis of trachoma. Microorganisms, 12:1544, Jul 2024. URL: https://doi.org/10.3390/microorganisms12081544, doi:10.3390/microorganisms12081544. This article has 5 citations.
(derrick2015trachomaandocular pages 5-6): Tamsyn Derrick, Chrissy h. Roberts, Anna R. Last, Sarah E. Burr, and Martin J. Holland. Trachoma and ocular chlamydial infection in the era of genomics. Mediators of Inflammation, Sep 2015. URL: https://doi.org/10.1155/2015/791847, doi:10.1155/2015/791847. This article has 41 citations and is from a peer-reviewed journal.
(atik2008identificationofnovel pages 2-3): Berna Atik, Troy A. Skwor, Ram Prasad Kandel, Bassant Sharma, Him Kant Adhikari, Lori Steiner, Henry Erlich, and Deborah Dean. Identification of novel single nucleotide polymorphisms in inflammatory genes as risk factors associated with trachomatous trichiasis. PLoS ONE, 3:e3600, Oct 2008. URL: https://doi.org/10.1371/journal.pone.0003600, doi:10.1371/journal.pone.0003600. This article has 34 citations and is from a peer-reviewed journal.
(natividad2007geneticvariationat pages 2-3): À. Natividad, À. Natividad, Neil A. Hanchard, Martin J. Holland, O. Mahdi, O. Mahdi, Mahamadou Diakite, K. Rockett, O. Jallow, H. Joof, Dominic P. Kwiatkowski, D. Mabey, and Robin L. Bailey. Genetic variation at the tnf locus and the risk of severe sequelae of ocular chlamydia trachomatis infection in gambians. Genes and Immunity, 8:288-295, Jun 2007. URL: https://doi.org/10.1038/sj.gene.6364384, doi:10.1038/sj.gene.6364384. This article has 67 citations and is from a peer-reviewed journal.
(atik2008identificationofnovel pages 1-2): Berna Atik, Troy A. Skwor, Ram Prasad Kandel, Bassant Sharma, Him Kant Adhikari, Lori Steiner, Henry Erlich, and Deborah Dean. Identification of novel single nucleotide polymorphisms in inflammatory genes as risk factors associated with trachomatous trichiasis. PLoS ONE, 3:e3600, Oct 2008. URL: https://doi.org/10.1371/journal.pone.0003600, doi:10.1371/journal.pone.0003600. This article has 34 citations and is from a peer-reviewed journal.
(paulet2024multimodalmucosaland pages 21-22): Elodie Paulet, Vanessa Contreras, Mathilde Galhaut, Ida Rosenkrands, Martin Holland, Matthew Burton, Jes Dietrich, Anne-Sophie Gallouet, Nathalie Bosquet, Francis Relouzat, Sébastien Langlois, Frank Follmann, Roger Le Grand, Marc Labetoulle, and Antoine Rousseau. Multimodal mucosal and systemic immune characterization of a non-human primate trachoma model highlights the critical role of local immunity during acute phase disease. PLOS Neglected Tropical Diseases, 18:e0012388, Aug 2024. URL: https://doi.org/10.1371/journal.pntd.0012388, doi:10.1371/journal.pntd.0012388. This article has 0 citations and is from a domain leading peer-reviewed journal.
(maciel2024trachomaassociatedmorbidityand pages 1-2): Adjoane Maurício Silva Maciel, Anderson Fuentes Ferreira, Nádia Maria Girão Saraiva de Almeida, Manuella Maurício Silva Maciel, Taynara Lais Silva, Mirele Coelho Araújo, Roberto da Justa Pires Neto, and Alberto Novaes Ramos Jr. Trachoma-associated morbidity and mortality in brazil: an ecological study focusing on hospitalization and mortality data, 2000−2022. Revista da Sociedade Brasileira de Medicina Tropical, Sep 2024. URL: https://doi.org/10.1590/0037-8682-0158-2024, doi:10.1590/0037-8682-0158-2024. This article has 1 citations.
(sitoe2024ongoingtransmissionof pages 2-3): Henis Sitoe, William Edward Oswald, Felizmina Zita, Mawo Fall, Tamimo Momade, Molly W Adams, Rebecca M Flueckiger, Scott McPherson, Sabrina Eyob, Thuy Doan, Thomas M Lietman, Benjamin F Arnold, Karana Wickens, Sarah Gwyn, Diana L Martin, Mabula Kasubi, Sarah Boyd, Ana Bakhtiari, Cristina Jimenez, Anthony W Solomon, Emma M Harding-Esch, and Jeremiah M Ngondi. Ongoing transmission of trachoma in low prevalence districts in mozambique: results from four cross-sectional enhanced impact surveys, 2022. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-71201-z, doi:10.1038/s41598-024-71201-z. This article has 3 citations and is from a peer-reviewed journal.
(sitoe2024ongoingtransmissionof pages 3-4): Henis Sitoe, William Edward Oswald, Felizmina Zita, Mawo Fall, Tamimo Momade, Molly W Adams, Rebecca M Flueckiger, Scott McPherson, Sabrina Eyob, Thuy Doan, Thomas M Lietman, Benjamin F Arnold, Karana Wickens, Sarah Gwyn, Diana L Martin, Mabula Kasubi, Sarah Boyd, Ana Bakhtiari, Cristina Jimenez, Anthony W Solomon, Emma M Harding-Esch, and Jeremiah M Ngondi. Ongoing transmission of trachoma in low prevalence districts in mozambique: results from four cross-sectional enhanced impact surveys, 2022. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-71201-z, doi:10.1038/s41598-024-71201-z. This article has 3 citations and is from a peer-reviewed journal.
(sitoe2024ongoingtransmissionof pages 4-6): Henis Sitoe, William Edward Oswald, Felizmina Zita, Mawo Fall, Tamimo Momade, Molly W Adams, Rebecca M Flueckiger, Scott McPherson, Sabrina Eyob, Thuy Doan, Thomas M Lietman, Benjamin F Arnold, Karana Wickens, Sarah Gwyn, Diana L Martin, Mabula Kasubi, Sarah Boyd, Ana Bakhtiari, Cristina Jimenez, Anthony W Solomon, Emma M Harding-Esch, and Jeremiah M Ngondi. Ongoing transmission of trachoma in low prevalence districts in mozambique: results from four cross-sectional enhanced impact surveys, 2022. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-71201-z, doi:10.1038/s41598-024-71201-z. This article has 3 citations and is from a peer-reviewed journal.
(antwiadjei2017relationshipbetweenthe pages 51-56): EK Antwi-Adjei. Relationship between the prevalence of trachomatous inflammation in children (age 1-9years) and the prevalence of trichiasis in adults (age 15years and above) at a …. Unknown journal, 2017.